---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-045300"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T02:07:23.979975+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode enters $1.08M equity line with White Lion Capital for TTX-MC138 development

## Summary
- Up to $1.08M in common stock purchase agreement with White Lion Capital; proceeds for working capital and TTX-MC138 development.
- Purchase price set at 92% of lower of 2-day VWAP or lowest closing price during valuation period.
- Commitment period ends May 31, 2023; if less than 1.5M shares sold by then, company must deliver shares to White Lion.
- Exchange cap of 3,163,124 shares (19.99% of outstanding) unless average price >= $0.39 or stockholder approval.
- Shares offered under effective shelf registration statement (File No. 333-268764).

## SEC filing metadata
- accession: 0001104659-23-045300
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/0001104659-23-045300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/tm2312650d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-045300
- JSON: https://secwatch.observer/filing/0001104659-23-045300.json
- Plain text: https://secwatch.observer/filing/0001104659-23-045300.txt

## Key facts
- Material Agreements
  Transcode Therapeutics, Inc. entered into White Lion Purchase Agreement with White Lion Capital, LLC valued at up to $1,081,307 (effective 2023-04-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: White Lion Capital, LLC
  - Value: up to $1,081,307
  - Effective: 2023-04-13
  source text: On April 13, 2023, TransCode Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC, a Nevada limited liability company (“White Lion”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/0001104659-23-045300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.